FDA — authorised 4 February 2022
- Marketing authorisation holder: BIOVERATIV THERAPEUTICS INC
- Status: approved
🇺🇸 Enjaymo in United States
FDA authorised Enjaymo on 4 February 2022
Marketing authorisations
FDA — authorised 4 February 2022
- Application: BLA761164
- Marketing authorisation holder: RECORDATI RARE DISEASES, INC.
- Local brand name: ENJAYMO
- Indication: INJECTABLE — INJECTION
- Status: approved
Enjaymo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Enjaymo approved in United States?
Yes. FDA authorised it on 4 February 2022; FDA authorised it on 4 February 2022.
Who is the marketing authorisation holder for Enjaymo in United States?
BIOVERATIV THERAPEUTICS INC holds the US marketing authorisation.